ProPhase Labs (ProPhase Labs) Debt-to-Equity

: 0.43 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

ProPhase Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.79 Mil. ProPhase Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18.59 Mil. ProPhase Labs's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $49.38 Mil. ProPhase Labs's debt to equity for the quarter that ended in Dec. 2023 was 0.43.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ProPhase Labs's Debt-to-Equity or its related term are showing as below:

PRPH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11 Med: 0.25 Max: 1.4
Current: 0.43

During the past 13 years, the highest Debt-to-Equity Ratio of ProPhase Labs was 1.40. The lowest was 0.11. And the median was 0.25.

PRPH's Debt-to-Equity is ranked worse than
61.93% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.24 vs PRPH: 0.43

ProPhase Labs Debt-to-Equity Historical Data

The historical data trend for ProPhase Labs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.40

0.25

0.11

0.43

ProPhase Labs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.11	0.24	0.28	0.33	0.43

Competitive Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProPhase Labs Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Debt-to-Equity falls into.

ProPhase Labs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ProPhase Labs's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.793	+	18.587)	/	49.383
	=	0.43

ProPhase Labs's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.793	+	18.587)	/	49.383
	=	0.43

ProPhase Labs (NAS:PRPH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ProPhase Labs Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ProPhase Labs (ProPhase Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530

Website

https://www.prophaselabs.com

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Executives

Morse Robert A. Jr.	officer: Controller	711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White	officer: Chief Financial Officer	191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr	director	902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel	10 percent owner	C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus	10 percent owner	188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch	director	621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady	officer: Chief Accounting Officer	621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr	officer: Chief Operating Officer	PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard	10 percent owner	156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal	10 percent owner	THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank	director	104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin	director
Mark A. Burnett	10 percent owner	40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley	director, 10 percent owner, officer: Chairman, President, CEO	C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo	10 percent owner	17 WOLCOTT COURT, BOSTON MA 02136